Business Context and Reporting Period
Lantheus Holdings, Inc. (LNTH) is a leading radiopharmaceutical-focused company committed to enabling clinicians to "Find, Fight, and Follow" disease. The company operates as a single segment, classifying products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. This Form 10-K covers the fiscal year ended December 31, 2025. During the period, Lantheus executed a major strategic pivot, acquiring Life Molecular Imaging Limited (LMI) and Evergreen Theragnostics, Inc., while simultaneously divesting its SPECT business to SHINE Technologies, LLC (completed January 1, 2026). The company also underwent a leadership transition, with Mary Anne Heino assuming the role of CEO effective January 1, 2026, following the retirement of Brian Markison.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $1,541.6 | $1,533.9 | +0.5% |
| Gross Profit | $942.0 | $988.3 | -4.7% |
| Operating Income | $310.8 | $457.0 | -32.0% |
| Net Income | $233.6 | $312.4 | -25.2% |
| Diluted EPS | $3.41 | $4.36 | -21.8% |
| Operating Cash Flow | $390.1 | $544.8 | -28.4% |
| Cash and Equivalents (Year End) | $359.1 | $912.8 | -60.7% |
| Debt Obligations | $575.0 (Convertible Notes) | $575.0 | 0% |
| Revolving Credit Facility | $750.0 (Available) | $350.0 (Available) | N/A |
Note: The decline in operating income and net income was primarily driven by increased operating expenses related to acquisitions, stock-based compensation, and litigation costs, partially offset by revenue growth from new acquisitions.
Material Changes vs. Prior Period
- Revenue Composition: While total revenue remained relatively flat, the mix shifted significantly. PYLARIFY revenue declined 6.5% to $989.1 million due to net price compression following the expiration of Transitional Pass-Through (TPT) status. Conversely, Precision Diagnostics revenue grew 12.7% to $493.1 million, driven by the inclusion of Neuraceq (acquired via LMI) and growth in DEFINITY.
- Acquisitions: The company spent approximately $575.6 million in cash on the acquisitions of Evergreen ($276.4 million) and Life Molecular ($355.2 million, net of working capital adjustments). These transactions added significant intangible assets and goodwill to the balance sheet.
- Expense Growth: General and Administrative (G&A) expenses surged 42.0% to $275.1 million, and R&D expenses increased 5.5% to $177.3 million. Increases were attributed to integration costs, stock-based compensation acceleration, and milestone payments (e.g., $10 million to AstraZeneca for NAV-4694).
- Divestiture: The SPECT business (TechneLite, NEUROLITE, Xenon Xe-133, Cardiolite) was classified as "held for sale" and subsequently sold in January 2026 for up to $155.0 million.
Guidance, Outlook, and Risks
Outlook and Pipeline: Management is focused on commercializing a new formulation of its PSMA PET imaging agent (PDUFA date March 6, 2026) and advancing Alzheimer's disease diagnostics (MK-6240 PDUFA date August 13, 2026; LNTH-2501 PDUFA date March 29, 2026). The company expects to seek TPT status for the new PSMA formulation to mitigate reimbursement headwinds.
Key Risks and Contingencies:
- Reimbursement Pressure: PYLARIFY lost TPT status on December 31, 2024. While CMS maintained separate payment based on Mean Unit Cost (MUC) for 2025 and 2026, the rate is lower than the previous Average Sales Price (ASP) based reimbursement, creating competitive pressure against newer agents retaining TPT status.
- Patent Litigation: The company is awaiting a court decision in a patent infringement lawsuit filed by Novartis entities regarding PNT2003. A negative outcome could delay or prevent the launch of this asset.
- Securities Litigation: A putative securities class action and a shareholder derivative action were filed in late 2025 alleging false or misleading statements. The outcome is uncertain and could result in significant costs.
- Integration Risks: The company faces execution risks in integrating Life Molecular and Evergreen, including potential unforeseen liabilities and the retention of key talent.
Investor Verification Checklist
- Reimbursement Trends: Verify the impact of the shift from ASP to MUC reimbursement on PYLARIFY net pricing and market share relative to competitors with active TPT status.
- Acquisition Integration: Monitor the realization of synergies and revenue contributions from the Life Molecular (Neuraceq) and Evergreen (CDMO/LNTH-2501) acquisitions in 2026.
- Regulatory Milestones: Track FDA decisions on the new PSMA formulation (March 2026), MK-6240 (August 2026), and LNTH-2501 (March 2026).
- Legal Outcomes: Assess the final ruling in the Novartis patent litigation regarding PNT2003 and the status of the securities class action.
- Debt Covenants: Confirm continued compliance with the 2022 Revolving Facility covenants, particularly the net leverage ratio, given the significant cash outflows for acquisitions and stock repurchases.